SCHEMBL2115276

SCHEMBL2115276

CC(=O)NC[C@@H]1CCN(c2nc3c(Cl)cccc3cc2[C@H](CC(C)(C)C)NC(=O)O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
CREBBP Q92793 1/20 0.36
DKK1 O94907 1/20 0.36
POLB P06746 1/20 0.36
PPARA Q07869 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
CNR2 P34972 5/20 0.35
ABL1 P00519 1/20 0.35
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
RBP4 P02753 1/20 0.34
TTR P02766 1/20 0.34
KCNH2 Q12809 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
ACACB O00763 1/20 0.34
CYP3A4 P08684 1/20 0.33
PTGFR P43088 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715570 0.88 CKS1B (0.39) CKS1BSKP1SKP2CREBBPDKK1
SCHEMBL715569 0.88 CKS1B (0.39) CKS1BSKP1SKP2CREBBPDKK1
SCHEMBL715571 0.88 CKS1B (0.39) CKS1BSKP1SKP2CREBBPDKK1
SCHEMBL2115271 0.82 POLB (0.39) CKS1BSKP1SKP2CREBBPDKK1
SCHEMBL16666211 0.82 SUV39H2 (0.41) CKS1BSKP1SKP2ABL1PDCD1
SCHEMBL16666212 0.82 SUV39H2 (0.41) CKS1BSKP1SKP2ABL1PDCD1
SCHEMBL16666213 0.82 SUV39H2 (0.41) CKS1BSKP1SKP2ABL1PDCD1
SCHEMBL2115279 0.80 CKS1B (0.39) CKS1BSKP1SKP2CREBBPDKK1
SCHEMBL2114949 0.80 CCNT1 (0.37) PDCD1CD274KCNH2CACNA1I
SCHEMBL17530817 0.79 CNR1 (0.37) POLBCNR2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA CKS1B 449/4885SKP1 313/4885SKP2 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.